About Human Genome Sciences
Human Genome Sciences is a Healthcare company based in Rockville (United States) founded in 1992, and was acquired by Samsung BioLogics in December 2025. Gene-based drugs for lupus, hepatitis C, inhalation anthrax and cancer. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its competitors include BeiGene, Moderna and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Human Genome Sciences was established in 1992 in Rockville, United States, within the biotechnology sector. Protein and antibody drugs were developed using human DNA sequences, targeting lupus, hepatitis C, inhalation anthrax, and cancer. A pipeline of seven products addressed autoimmune diseases, anthrax exposure, and oncology. Collaboration with Cambridge Antibody Technology yielded therapeutics such as belimumab and raxibacumab. Acquisition by GlaxoSmithKline occurred in 2012 for 3 billion.
- InvestorsGSK
& 1 more
- Acquired by
Investors in Human Genome Sciences
Human Genome Sciences has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include GSK and Samsung BioLogics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom | |
Contract development and manufacturing for biologics are provided. | 2011 | samsungbiologics.com | Incheon, South Korea |
Investor details for Human Genome Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Human Genome Sciences
3 dated milestones of Human Genome Sciences across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Human Genome Sciences is founded.
- Exit Acquired by GSK.
- Exit Acquired by Samsung BioLogics.
Competitors of Human Genome Sciences
Human Genome Sciences has 3 listed competitors in our database, 2 of them funded. They include BeiGene, Moderna and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Human Genome Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Human Genome Sciences
Websites that share an audience with Human Genome Sciences (hgsi.com).
Websites whose visitors overlap most with Human Genome Sciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| merck.com | 100% | 656.8K | #78,842 | View details | |
| amgen.com | 100% | 495.4K | #116,434 | View details | |
| elan.com | 100% | View details | |||
| pfizer.com | 100% | 1.9M | #24,984 | View details | |
| sciclone.com | 98% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 24 similar websites and full traffic analytics for Human Genome Sciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 24 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Human Genome Sciences (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Human Genome Sciences
Complete news archive for Human Genome Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Human Genome Sciences
Human Genome Sciences was founded in 1992.
Human Genome Sciences is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Human Genome Sciences was established in 1992 in Rockville, United States, within the biotechnology sector. Protein and antibody drugs were developed using human DNA sequences, targeting lupus, hepatitis C, inhalation anthrax, and cancer. A pipeline of seven products addressed autoimmune diseases, anthrax exposure, and oncology. Collaboration with Cambridge Antibody Technology yielded therapeutics such as belimumab and raxibacumab. Acquisition by GlaxoSmithKline occurred in 2012 for 3 billion.
Human Genome Sciences has 2 investors. Key investors include GSK, and Samsung BioLogics.
Yes. Human Genome Sciences was acquired by GSK in July 2012.